Gufic Biosciences Ltd
NSE:GUFICBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Gufic Biosciences Ltd
NSE:GUFICBIO
|
IN |
|
Z
|
Zhejiang Anglikang Pharmaceutical Co Ltd
SZSE:002940
|
CN |
|
Seazen Group Ltd
HKEX:1030
|
CN |
|
Inner Mongolia Dazhong Mining Co Ltd
SZSE:001203
|
CN |
|
Mic AG
XETRA:M3BK
|
DE |
|
Guang Dong High Dream Intellectualized Machinery Co Ltd
SZSE:300720
|
CN |
Gufic Biosciences Ltd
Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-10-19. The firm operates through Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash, and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole, Everolimus. Its Gufic Stridden includes Irvical and Eve.
Gufic Biosciences Ltd. engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2004-10-19. The firm operates through Pharmaceutical segment. The company has pharmaceutical products under categories, such as Criti Care, including Doxific, Micafung, Rabol and Tigefic-Plus; Criticare Life, including Ticofic-200 and Gufivan-500; Ferticare, including Puregraf 75IU 3D, Cetrocare 0.25mg 3D and Follicare 150IU 3D; Spark, including Aznee Duo, Eclin, Flabone, Vipro M and Zad G; Herbal, including Bocomo-Forte, Sallaki-Liniment, Zulcer Cap and Smashit tablet, and Aesthaderm, including Prosil, Moiseta Face Wash, and Revanox Serum. Its personal care products include StretchNil, Shapers-Natural Feel, Shaper-DryFeel and RollOn. Its products under active pharmaceutical ingredient (API)/bulk drugs include Micafungin, Anidulafungin, Sulconazole, Everolimus. Its Gufic Stridden includes Irvical and Eve.
Revenue Flat QoQ: Q3 turnover was INR 231.1 crores, nearly unchanged from Q2's INR 230.4 crores, with management attributing the lack of growth to working capital discipline and strategic write-offs in the domestic hospital business.
Margins Stable: EBITDA margin for Q3 was 16.05%, slightly down from 16.45% in Q2, while PAT margin improved modestly to 6.75%. Gross margins were not a concern according to management.
Strategic Shift Domestic: The company is moving away from direct-to-hospital sales and tightening debtor controls in its Sparsh and Critical Care divisions, incurring an intentional hit to revenue this quarter (INR 14–16 crores) to improve future working capital.
Indore Ramp-Up: Indore plant output and utilization are rising, with Q3 output moving from INR 20–25 crores per quarter to INR 36–38 crores, and further growth expected. EU GMP audit was completed, and exports from Indore to regulated markets are expected to begin by Q3/Q4 next year.
Guidance Reiterated: Management guided for at least 15% top-line growth in FY '27, with a focus on sustainable execution and working capital discipline, and indicated margin improvement as Indore utilization increases.
Segmental Performance: International business and Ferticare segments saw strong growth, while domestic branded business was up around 8%. Botulinum toxin and infertility products posted 20%+ growth but from a low base.
